Login / Register Submit Your Article
cover
Article Menu
Journal Browser
Vol. 1 (2024)
Indexing and Partners

Google scholar

Crossref

Multiple myeloma Clinical testing Bibliometric analysis Research trends Therapeutic strategies Collaboration networks. Transgender Hormone misuse Gender-affirming treatment Sex hormone drugs Lung adenocarcinoma Screen Surveillance Accessibility Lung cancer Equity
Open Access Journal Article

Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study

by Hongcheng Wu 1 ,  Haomiao Sun 1 ,  Yichen Wang 1 ,  Zehui Lv 1 ,  Yingshuo Li 1 ,  Fangzheng Su 1 ,  Chiyi Liu 1 ,  Yuxin Chen 1 ,  Kun Shi 1 ,  Pengyu Zhao 1  and  Xinyu Wu 1,*
1
School of Pharmacy and Pharmaceutical Sciences (Institute of Pharmaceutical Sciences), Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan 250117, China
*
Author to whom correspondence should be addressed.
JMMR  2025 1(1):3; https://doi.org/10.69638/jmmr20210110X
Received: 19 June 2024 / Accepted: 8 January 2025 / Published Online: 15 January 2025
View Full-Text
Download PDF

Abstract

Objective: This study investigates the development trends and research hotspots in clinical testing for multiple myeloma from 2000 to 2023, using bibliometric techniques.

Method: Search for relevant literature on clinical testing of multiple myeloma published in the Web of Science Core Collection (WoSCC) from 2000 to 2023, and use CiteSpace 6.2.R4 software to draw a visual knowledge map of authors, research institutions, national and regional cooperation networks, journals, and keywords, and conduct bibliometric analysis.

Results: The study found an upward trend in publications over the specified period, with significant growth noted from 2012 onwards. The majority of research originates from the United States, with significant contributions from institutions like the Mayo Clinic and MD Anderson Cancer Center. Analysis of author collaboration networks indicated relatively low centrality, suggesting minimal collaboration among researchers. Bibliometric mapping highlighted several hotspots in the field including therapeutic strategies involving proteasome inhibitors and immunomodulatory drugs, the role of stem cell transplantation, and the importance of achieving and monitoring minimal residual disease.

Conclusion: The field of clinical testing for multiple myeloma is characterized by a growing body of research, with significant contributions from the United States. Despite the increasing volume of research, there is a need for enhanced collaboration among researchers and institutions to consolidate findings and advance clinical practice.

Keywords: Multiple myeloma; Clinical testing; Bibliometric analysis; Research trends; Therapeutic strategies; Collaboration networks.;
Copyright: © 2025 by Wu, Sun, Wang, Lv, Li, Su, Liu, Chen, Shi, Zhao and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Cite This Paper
APA Style
Wu, H., Sun, H., Wang, Y., Lv, Z., Li, Y., Su, F., Liu, C., Chen, Y., Shi, K., Zhao, P., & Wu, X. (2024). Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study. Journal of medical management research, 1(1), 3. doi:10.69638/jmmr20210110X
ACS Style
Wu, H.; Sun, H.; Wang, Y.; Lv, Z.; Li, Y.; Su, F.; Liu, C.; Chen, Y.; Shi, K.; Zhao, P., et al. Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study. Journal of medical management research, 2024, 1, 3. doi:10.69638/jmmr20210110X
AMA Style
Wu H, Sun H, Wang Y et al.. Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study. Journal of medical management research; 2024, 1(1):3. doi:10.69638/jmmr20210110X
Chicago/Turabian Style
Wu, Hongcheng; Sun, Haomiao; Wang, Yichen; Lv, Zehui; Li, Yingshuo; Su, Fangzheng; Liu, Chiyi, and et al. 2024. "Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study" Journal of medical management research 1, no.1:3. doi:10.69638/jmmr20210110X

Share and Cite

ACS Style
Wu, H.; Sun, H.; Wang, Y.; Lv, Z.; Li, Y.; Su, F.; Liu, C.; Chen, Y.; Shi, K.; Zhao, P., et al. Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study. Journal of medical management research, 2024, 1, 3. doi:10.69638/jmmr20210110X
AMA Style
Wu H, Sun H, Wang Y et al.. Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study. Journal of medical management research; 2024, 1(1):3. doi:10.69638/jmmr20210110X
Chicago/Turabian Style
Wu, Hongcheng; Sun, Haomiao; Wang, Yichen; Lv, Zehui; Li, Yingshuo; Su, Fangzheng; Liu, Chiyi, and et al. 2024. "Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study" Journal of medical management research 1, no.1:3. doi:10.69638/jmmr20210110X
APA style
Wu, H., Sun, H., Wang, Y., Lv, Z., Li, Y., Su, F., Liu, C., Chen, Y., Shi, K., Zhao, P., & Wu, X. (2024). Development Trends in the Clinical Test of Multiple Myeloma from 2000 to 2023: A Bibliometric Study. Journal of medical management research, 1(1), 3. doi:10.69638/jmmr20210110X

Article Metrics

Article Access Statistics

References

  1. Da Vià M C, Ziccheddu B, Maeda A. A journey through myeloma evolution: from the normal plasma cell to disease complexity. HemaSphere, 2020, 4(6): e502.
  2. Abduh M S. An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities. Saudi Journal of Biological Sciences, 2024, 31(2): 103920.
  3. Han W, Jin Y, Xu M. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma. Hematology, 2021, 26(1): 510-517.
  4. Firsova M V, Mendeleeva L P, Kovrigina A M. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry. BMC cancer, 2020, 20: 1-8.
  5. Furukawa Y, Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. International journal of hematology, 2020, 111(4): 496-511.
  6. Fitzpatrick M J, Nardi V, Sohani A R. Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiology, 2022: 1-14.
  7. Solimando A G, Vacca A, Ribatti D. A Comprehensive Biological and Clinical Perspective Can Drive a Patient‐Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche. Journal of Oncology, 2020, 2020(1): 6820241.
  8. Bonsignore M, Trusso S, De Pasquale C. A multivariate analysis of Multiple Myeloma subtype plasma cells. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2021, 258: 119813.
  9. Bladé J, Beksac M, Caers J. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer Journal, 2022, 12(3): 45.
  10. Gupta N, Sharma A, Sharma A. Emerging biomarkers in multiple myeloma: a review. Clinica chimica acta, 2020, 503: 45-53.
  11. Urban V S, Cegledi A, Mikala G. Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment. Geroscience, 2023, 45(2): 727-746.
  12. Madu A J, Nonyelu C, Okoye H C. Multiple Myeloma: An In-depth Review of the Historical and Pathogenetic Processes. Asian Hematology Research Journal, 2021, 4(4): 21-33.
  13. Murray D L, Puig N, Kristinsson S. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood cancer journal, 2021, 11(2): 24.
  14. Liu Y, Jelloul F, Zhang Y. Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. The American journal of surgical pathology, 2020, 44(6): 838-848.
  15. Liang Y, He H, Wang W. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. Molecular Cancer, 2022, 21(1): 182.
  16. Dutta A K, Alberge J B, Sklavenitis-Pistofidis R. Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine. Nature Reviews Clinical Oncology, 2022, 19(4): 223-236.
  17. Liu R, Gao Q, Foltz S M. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nature communications, 2021, 12(1): 2559.
  18. Souza L L, Caceres C V B L, Vargas P A. Plasmacytoma and plasma cell myeloma affecting the jaws: A multi‐institutional collaborative study. Journal of Oral Pathology & Medicine, 2021, 50(6): 613-621.
  19. Méndez-Ferrer S, Bonnet D, Steensma D P. Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20(5): 285-298.
  20. Di Giuliano F, Picchi E, Muto M. Radiological imaging in multiple myeloma: review of the state-of-the-art. Neuroradiology, 2020, 62(8): 905-923.
  21. Casey M, Nakamura K. The cancer-immunity cycle in multiple myeloma. ImmunoTargets and Therapy, 2021: 247-260.
  22. Simsek Z, Fox B, Heavey C. Systematicity in organizational research literature reviews: A framework and assessment. Organizational Research Methods, 2023, 26(2): 292-321.
  23. Grant M J, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health information & libraries journal, 2009, 26(2): 91-108.
  24. Keathley-Herring H, Van Aken E, Gonzalez-Aleu F. Assessing the maturity of a research area: bibliometric review and proposed framework. Scientometrics, 2016, 109: 927-951.
  25. Jain G, Das N, Gajendra S. Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders. International Journal of Laboratory Hematology, 2022, 44(5): 837-845.
  26. Wu X, Zhou Z, Cao Q. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review. Frontiers in immunology, 2023, 14: 1268188.
  27. Hemminki K, Försti A, Houlston R. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. International journal of cancer, 2021, 149(12): 1980-1996.
  28. Liu R, Liu J, Cao Q. Identification of crucial genes through WGCNA in the progression of gastric cancer. Journal of Cancer, 2024, 15(11): 3284.
  29. Cao Q, Wu X, Zhang Q. Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review. Frontiers in Pharmacology, 2023, 14: 1291920.
  30. Wallington-Beddoe C T, Mynott R L. Prognostic and predictive biomarker developments in multiple myeloma. Journal of hematology & oncology, 2021, 14: 1-15.
  31. You Y, Chen Y, Wang X. Accelerometer-measured physical activity patterns are associated with phenotypic age: Isotemporal substitution effects. Heliyon, 2023, 9(9).
  32. Braunlin M, Belani R, Buchanan J. Trends in the multiple myeloma treatment landscape and survival: a US analysis using 2011–2019 oncology clinic electronic health record data. Leukemia & Lymphoma, 2021, 62(2): 377-386.
  33. Cao Q, Wu X, Chen Y. The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study. Frontiers in cellular and infection microbiology, 2023, 13: 1257638.
  34. Yang P, Qu Y, Wang M. Pathogenesis and treatment of multiple myeloma. MedComm, 2022, 3(2): e146.
  35. Welters C, Lammoglia Cobo M F, Stein C A. Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma. Cancer Immunology Research, 2022, 10(11): 1407-1419.
  36. Cao Q, Zhang Q, Chen Y Q. Risk factors for the development of hepatocellular carcinoma in Chengdu: a prospective cohort study. European review for medical and pharmacological sciences, 2022, 26(24): 9447-9456.
  37. Medina A, Jiménez C, Sarasquete M E. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood cancer journal, 2020, 10(2): 14.
  38. Binder M, Nandakumar B, Rajkumar S V. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36(3): 801-808.
  39. Cao Q, Zhu J, Wu X. Efficacy and safety assessment of intrathoracic perfusion chemotherapy combined with immunological factor interleukin-2 in the treatment of advanced non-small cell lung cancer: a retrospective cohort study. Journal of Cancer, 2024, 15(7).
  40. You Y, Chen Y, Wei M. Mediation role of recreational physical activity in the relationship between the dietary intake of live microbes and the systemic immune-inflammation index: A real-world cross-sectional study. Nutrients, 2024, 16(6): 777.
  41. Cao Q, Wang Q, Wu X. A literature review: mechanisms of antitumor pharmacological action of leonurine alkaloid. Frontiers in pharmacology, 2023, 14: 1272546.
  42. Gunes E G, Gunes M, Yu J. Targeting cancer stem cells in multiple myeloma. Trends in Cancer, 2024.
  43. García-Sánchez D, González-González A, Alfonso-Fernández A. Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression. World Journal of Stem Cells, 2023, 15(5): 421.
  44. Li X, Xu H, Du Z. Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer. Frontiers in Oncology, 2024, 14: 1382701.
  45. Borgatti A. Plasma cell tumors. Schalm's veterinary hematology, 2022: 588-598.
  46. Saidi I, Batahar S A, Amro L. A case of Multiple Myeloma with lung plasmacytoma. Respiratory Medicine Case Reports, 2022, 39: 101713.
  47. Bou Zerdan M, Nasr L, Kassab J. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. International Journal of Hematologic Oncology, 2022, 11(2): IJH39.